Dealmaking

CD&R partners with Millennium Physician Group

Millennium is one of Florida's largest independent primary care practices with more than 300 healthcare and around 200 primary care providers.

Leon Black leaves Apollo earlier than expected, former SEC chair Clayton succeeds him as chair: WSJ

Black is citing his and his wife’s health issues as key reasons for the unexpected move.

Private Equity Jobs of the Week: Carlyle, First Capital and Saw Mill are hiring

This week’s positions include a principal at Savano, a VP at Carlyle and an associate at Saw Mill.

Clearlake, Insight-backed Appriss snags PatientPing

The $500m deal will diversify Appriss's offerings in healthcare, adding care collaboration tools that help drive cost savings across the ecosystem.

Calypso goes to Thoma Bravo, Why H&F, Warburg-backed Edelman is staying private, Growthy healthcare assets ready IPOs

Thoma Bravo buys Calypso Technology and CD&R’s Agilon Health files to raise up to $100 million for its IPO.

Blue Point acquires a $100m leather manufacturer

River Associates-backed Weaver Leather gets sold to Blue Point, marking the company’s third partnership with institutional money.

H&F-backed Edelman Financial Engines, after Warburg investment, sees advantage in staying private

The $7.3bn deal values H&F’s 2018 investment north of 2x and its original 2015 investment a little over 4x, a source with knowledge of the matter told PE Hub.

Goldman Sachs Working Conditions Survey creates noise, Silver Lake backs legal-tech company Relativity

Goldman Sachs releases study of analysts' working conditions and Silver Lake invests in Relativity Trace.

In your words: lack of women in deal leadership in PE, CD&R leads investor group in $100m investment in M2GEN

CD&R leads an investor group that injects $100 million in M2GEN and exploring the lack of women in deal leadership in private equity

CD&R-led investor group injects $100m into M2GEN, looking to transform cancer care with data

A crucial component of the transaction, CD&R's Sarah Kim says, was helping to reawaken the commercial relationship between pharmaceutical giant Merck and the data and informatics business.